Lodo Therapeutics enters into drug discovery collaboration with Genentech

| By | Drug Development

Lodo Therapeutics Corporation, a drug discovery and development company focused on identifying and producing unique, bioactive natural products directly from the microbial DNA sequence information contained in soil, formed a strategic drug discovery collaboration with Genentech, a member of the Roche Group.

Genentech will utilize Lodo Therapeutics’ proprietary genome mining and biosynthetic cluster assembly platform to identify novel molecules with therapeutic potential against multiple disease-related targets of interest to Genentech. Lodo will receive an undisclosed upfront payment and is eligible to receive research, development and commercialization milestone payments up to $969 million based on achievement of certain predetermined milestones. In addition, Lodo is eligible to receive tiered-royalties on sales of certain products resulting from the collaboration.

Compounds derived from natural products comprise a significant proportion of the small molecule drugs used to treat cancer, infections and chronic illnesses such as Type 2 diabetes. Rather than relying on culturing known strains of bacteria, Lodo Therapeutics’ genome-based approach leverages the power of microbial evolution to identify novel, naturally occurring compounds that have therapeutic potential in the treatment of cancer and drug-resistant bacterial infections. This approach is expected to reduce the time and cost of drug discovery.

Lodo Therapeutics Corporation is a US drug discovery and development company focused on the creation of novel therapeutics derived from nature that will impact patients around the world. The company was established to pursue the scientific vision of Dr. Sean Brady, head of The Rockefeller University’s Laboratory of Genetically Encoded Small Molecules.

Genentech, Inc., is a biotechnology corporation which became a subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche

SOURCE: lodo therapeutics
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.